Edition:
United States

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

16.53USD
21 Apr 2017
Change (% chg)

$-0.56 (-3.28%)
Prev Close
$17.09
Open
$17.12
Day's High
$17.21
Day's Low
$16.50
Volume
410,578
Avg. Vol
432,439
52-wk High
$20.90
52-wk Low
$4.36

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics prices 4.45 mln share offering at $18 per share
Thursday, 30 Mar 2017 09:35pm EDT 

Cara Therapeutics Inc : Cara Therapeutics announces pricing of its public offering of common stock .Says public offering of 4.45 million common shares priced at $18 per share.  Full Article

Cara Therapeutics announces proposed offering of common stock
Wednesday, 29 Mar 2017 04:01pm EDT 

Cara Therapeutics Inc : Cara Therapeutics announces proposed offering of common stock . Cara Therapeutics Inc - commenced an underwritten public offering of $80 million of shares of its common stock .Cara Therapeutics Inc - proceeds of offering are expected to be used to fund company's clinical and research development activities.  Full Article

Cara Therapeutics announces positive top-line data from Part A of Phase 2/3 Trial of I.V. CR845 in chronic kidney disease-associated pruritus
Tuesday, 28 Mar 2017 07:00am EDT 

Cara Therapeutics Inc : Cara Therapeutics announces positive top-line data from part A of phase 2/3 trial of I.V. CR845 in chronic kidney disease-associated pruritus . Trial met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (P<0.0019) . Trial met secondary endpoint in quality of life domains versus placebo after eight-week treatment period . I.V. CR845 well tolerated after eight weeks of treatment .Plans to meet with U.S. FDA for end-of-phase 2 meeting to review results to determine optimal dose to take into part B of Phase 2/3 study.  Full Article

Cara files for mixed shelf of up to $250.0 mln
Monday, 13 Mar 2017 04:40pm EDT 

Cara Therapeutics Inc :Files for mixed shelf of up to $250.0 million - sec filing.  Full Article

Cara Therapeutics Q4 loss per share $0.81
Thursday, 9 Mar 2017 04:01pm EST 

Cara Therapeutics Inc : Cara Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.81 . Q4 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S .Cara Therapeutics - expects that cash equivalents as of Dec 31, 2016 to be sufficient to fund operating, capital expenditures through end of Q1 2018.  Full Article

Cara Therapeutics reports Q3 loss per share $0.42
Thursday, 3 Nov 2016 04:01pm EDT 

Cara Therapeutics Inc : Cara therapeutics inc- top line data expected in 1h 2017 from three late-stage clinical programs . Cara therapeutics-expects existing cash,cash equivalents will be sufficient to fund operating and capital expenditure requirements through end of q1 2018 . Cara therapeutics reports third quarter 2016 financial results . Q3 loss per share $0.42 .Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.  Full Article

Cara therapeutics posts Q2 shr loss $0.48
Thursday, 4 Aug 2016 04:01pm EDT 

Cara Therapeutics Inc : Q2 loss per share $0.48 . Cara therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.  Full Article

Cara Therapeutics resumes patient recruitment
Monday, 6 Jun 2016 07:00am EDT 

Cara Therapeutics Inc : Resumed patient recruitment after FDA removed clinical hold on CLIN3001 adaptive phase 3 trial of I.V. CR845 for postoperative pain . Study will continue as a three-arm trial comparing two doses of CR845 (1.0 and 0.5 ug/kg) to placebo . To provide updates on progress of trial later this year .Cara Therapeutics resumes patient recruitment for adaptive phase 3 trial of I.V. CR845 in postoperative pain.  Full Article

Cara therapeutics announces removal of FDA clinical hold on I.V. CR845 trial
Wednesday, 20 Apr 2016 07:00am EDT 

Cara therapeutics:Therapeutics announces removal of FDA clinical hold on clin3001 postoperative pain trial for i.v. Cr845.Received notice from fda that it has removed clinical hold on adaptive phase 3 trial of i.v. Cr845 for postoperative pain.Based on safety review study will continue as a three-arm trial testing two doses of cr845 (1 ug/kg and 0.5 ug/kg) versus placebo.  Full Article

Cara Therapeutics announces positive top-line results from Phase 2a Trial of Oral CR845 in chronic pain patients with osteoarthritis of the knee or hip
Wednesday, 9 Dec 2015 07:00am EST 

Cara Therapeutics Inc:Says all four tablet strengths observed to be safe and well tolerated.Says establishes therapeutic doses and dosing regimen for phase 2b trial in 2016.Says dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks.Says observed statistically significant reduction in mean rescue medication for top 5.0 mg dose.  Full Article

More From Around the Web